MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

MLTX Stock Forecast


MoonLake Immunotherapeutics stock forecast is as follows: an average price target of $79.33 (represents a 52.97% upside from MLTX’s last price of $51.86) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

MLTX Price Target


The average price target for MoonLake Immunotherapeutics (MLTX) is $79.33 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $62.00. This represents a potential 52.97% upside from MLTX's last price of $51.86.

MLTX Analyst Ratings


Buy

According to 7 Wall Street analysts, MoonLake Immunotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for MLTX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

MoonLake Immunotherapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 01, 2024Raghuram SelvarajuH.C. Wainwright$100.00$43.97127.43%92.83%
Apr 02, 2024Richard LawGoldman Sachs$62.00$48.6027.57%19.55%
Aug 31, 2023Serge BelangerNeedham$76.00$56.0935.48%46.55%
Row per page
Go to

The latest MoonLake Immunotherapeutics stock forecast, released on Jul 01, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $100.00, which represents a 127.43% increase from the stock price at the time of the forecast ($43.97), and a 92.83% increase from MLTX last price ($51.86).

MoonLake Immunotherapeutics Price Target by Period


1M3M12M
# Anlaysts--2
Avg Price Target--$81.00
Last Closing Price$51.86$51.86$51.86
Upside/Downside-100.00%-100.00%56.19%

In the current month, the average price target of MoonLake Immunotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MoonLake Immunotherapeutics's last price of $51.86. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2024H.C. WainwrightBuyBuyHold
Sep 12, 2024Cowen & Co.BuyBuyHold
Sep 12, 2024H.C. WainwrightBuyBuyHold
Aug 26, 2024Wolfe Research-Peer PerformDowngrade
Jul 01, 2024H.C. WainwrightBuyBuyHold
Jun 24, 2024Oppenheimer-OutperformInitialise
Apr 02, 2024Goldman Sachs-NeutralInitialise
Aug 31, 2023Needham-BuyInitialise
Feb 14, 2023Cantor Fitzgerald-OverweightInitialise
Nov 11, 2022Jefferies-BuyInitialise
Row per page
Go to

MoonLake Immunotherapeutics's last stock rating was published by H.C. Wainwright on Oct 15, 2024. The company gave MLTX a "Buy" rating, the same as its previous rate.

MoonLake Immunotherapeutics Financial Forecast


MoonLake Immunotherapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

MoonLake Immunotherapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. MLTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

MoonLake Immunotherapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict MLTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than MoonLake Immunotherapeutics's previous annual EBITDA (undefined) of $NaN.

MoonLake Immunotherapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-42.14M$-44.03M$-41.51M$-39.00M$-37.63M$-27.39M$-17.41M
High Forecast$-42.14M$-44.03M$-41.51M$-33.15M$-27.31M$-27.39M$-17.41M
Low Forecast$-42.14M$-44.03M$-41.51M$-44.85M$-46.13M$-27.39M$-17.41M
Surprise %-------

MoonLake Immunotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MLTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

MoonLake Immunotherapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

MoonLake Immunotherapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to MLTX last annual SG&A of $NaN (undefined).

MoonLake Immunotherapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.67$-0.70$-0.66$-0.62$-0.60$-0.44$-0.28
High Forecast$-0.67$-0.70$-0.66$-0.53$-0.43$-0.44$-0.28
Low Forecast$-0.67$-0.70$-0.66$-0.71$-0.73$-0.44$-0.28
Surprise %-------

According to undefined Wall Street analysts, MoonLake Immunotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MLTX previous annual EPS of $NaN (undefined).

MoonLake Immunotherapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$1.73$33.861857.23%Buy
AVTEAerovate Therapeutics$2.61$13.00398.08%Hold
CMPXCompass Therapeutics$1.38$5.00262.32%Buy
PLRXPliant Therapeutics$12.85$39.71209.03%Buy
GPCRStructure Therapeutics$30.10$92.40206.98%Buy
ABOSAcumen Pharmaceuticals$2.31$7.00203.03%Buy
DAWNDay One Biopharmaceuticals$13.34$38.80190.85%Buy
ETNB89bio$8.38$22.00162.53%Buy
TERNTerns Pharmaceuticals$5.71$14.25149.56%Buy
ELVNEnliven Therapeutics$25.41$39.5055.45%Buy
MLTXMoonLake Immunotherapeutics$51.86$79.3352.97%Buy
AKROAkero Therapeutics$31.20$46.0047.44%Buy
AMLXAmylyx Pharmaceuticals$5.19$6.6728.52%Buy
NUVLNuvalent$92.73$111.5720.32%Buy
TVTXTravere Therapeutics$18.26$21.7519.11%Buy
ACLXArcellx$87.22$83.00-4.84%Buy
CERECerevel Therapeutics$44.96$33.50-25.49%Buy

MLTX Forecast FAQ


Is MoonLake Immunotherapeutics a good buy?

Yes, according to 7 Wall Street analysts, MoonLake Immunotherapeutics (MLTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of MLTX's total ratings.

What is MLTX's price target?

MoonLake Immunotherapeutics (MLTX) average price target is $79.33 with a range of $62 to $100, implying a 52.97% from its last price of $51.86. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will MoonLake Immunotherapeutics stock go up soon?

According to Wall Street analysts' prediction for MLTX stock, the company can go up by 52.97% (from the last price of $51.86 to the average price target of $79.33), up by 92.83% based on the highest stock price target, and up by 19.55% based on the lowest stock price target.

Can MoonLake Immunotherapeutics stock reach $80?

MLTX's highest twelve months analyst stock price target of $100 supports the claim that MoonLake Immunotherapeutics can reach $80 in the near future.

What are MoonLake Immunotherapeutics's analysts' financial forecasts?

MoonLake Immunotherapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-82.435M (high $-72.116M, low $-90.933M), average SG&A $0 (high $0, low $0), and average EPS is $-1.311 (high $-1.147, low $-1.446). MLTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-167M (high $-161M, low $-173M), average SG&A $0 (high $0, low $0), and average EPS is $-2.65 (high $-2.557, low $-2.743).